Research Article
Different Clinical Utility of Oropharyngeal Bacterial Screening prior to Percutaneous Endoscopic Gastrostomy in Oncological and Neurological Patients
Table 1
Summary of patient characteristics according to indication for PEG (
).
| Variable | Neurological disorders () | Head and neck cancer () | | | % | | % |
| Sex (male) | 116 | 56.3% | 45 | 66.2% | 0.159 | Colonizing pathogens | 159 | 77.2% | 31 | 45.6% | <0.001* | Polymicrobial flora | 75 | 36.4% | 12 | 17.6% | 0.004* | Pathogens resistant to amoxicillin | 93 | 45.1% | 12 | 17.6% | <0.001* | Tracheostomy | 67 | 32.5% | 13 | 19.1% | 0.045* | MRSA infection | 11 | 5.3% | 0 | 0.0% | 0.071 | ATB prophylaxis | 206 | 100.0% | 68 | 100.0% | 1.000 | Coamoxicillin | 196 | 95.1% | 66 | 97.1% | 0.736 | Cefuroxim | 3 | 1.5% | 1 | 1.5% | 1.000 | Other | 7 | 3.4% | 1 | 1.5% | 0.684 | Serious comorbidities | 32 | 15.5% | 7 | 10.3% | 0.324 | PEG site infections | 18 | 8.7% | 12 | 17.6% | 0.070 | Other complications | 17 | 8.3% | 12 | 17.6% | 0.040* | Major complications (bleeding, respiratory) | 5 | 2.4% | 6 | 8.8% | 0.027* | Minor complications | 12 | 5.8% | 6 | 8.8% | 0.394 | 30 days of mortality | 19 | 9.2% | 1 | 1.5% | 0.032* |
|
|
Statistically significant at 5% level.
|